Diagnostic specificity of two dengue virus IgG ELISAs after yellow fever and Japanese encephalitis virus vaccination

• Published in: Tropical medicine and infectious disease Vol. 8; no. 1; pp. 1 - 11
• Main Authors: Isabelle Schnabel, Sophie Schneitler, Tom Schuttoff, Henning Trawinski, Christoph Lubbert, Christian Jassoy
• Format: Journal Article
• Published: Basel, Switzerland MDPI 01.01.2023
• Subjects: Dengue viruses; Flaviviruses; Health aspects; Vaccination; Vaccines; Virus diseases
• ISSN: 2414-6366; 2414-6366

Dengue virus (DENV) antibody assays frequently cross-react with sera from individuals who have been infected with or vaccinated against related flaviviruses. The goal of this study was to determine the specificity of two DENV ELISAs with sera from individuals vaccinated against yellow fever virus (YFV) and Japanese encephalitis virus (JEV). The Panbio and theNovatec Dengue IgG ELISAs were tested with sera obtained 3-4 weeks or 0.5-6 years after YFV or JEV vaccination and the diagnostic specificity of the assays was determined. As controls, the sera were tested using DENV, YFV, JEV, Zika and West Nile virus neutralization assays. The diagnostic specificity of the Panbio and the Novatec ELISA with sera from YFV-vaccinated subjects was 98.2% and 88.2%, respectively. Cross-reactions were rare in the first 4 weeks despite high YFV-neutralizing antibody titers and were mostly found later. The specificity of the Panbio and Novatec assays with sera from JEV-vaccinated individuals was 100% and 92.9%. Cross-reactions occurred in the early time period after vaccination. The measurement values of the two ELISAs correlated strongly. Thus, the Panbio ELISA showed higher diagnostic specificity and may be suitable for seroprevalence studies in areas with high disease prevalence.